Catalyst Pharmaceuticals Inc
$ 31.36
-0.03%
12 Jun - close price
- Market Cap 3,840,308,000 USD
- Current Price $ 31.36
- High / Low $ 31.39 / 31.35
- Stock P/E 18.13
- Book Value 8.29
- EPS 1.73
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.16 %
- ROE 0.24 %
- 52 Week High 32.56
- 52 Week Low 19.05
About
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, neuromuscular, and chronic neurological diseases in the United States. The company is headquartered in Coral Gables, Florida.
Analyst Target Price
$32.75
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-11 | 2026-02-25 | 2025-11-05 | 2025-08-06 | 2025-05-07 | 2025-02-26 | 2024-11-06 | 2024-08-07 | 2024-05-08 | 2024-02-28 | 2023-11-08 | 2023-08-09 |
| Reported EPS | 0.79 | 0.68 | 0.42 | 0.41 | 0.45 | 0.44 | 0.35 | 0.33 | 0.19 | 0.31 | -0.29 | 0.53 |
| Estimated EPS | 0.6428 | 0.298 | 0.33 | 0.39 | 0.34 | 0.32 | 0.3 | 0.26 | 0.17 | 0.27 | -0.28 | 0.42 |
| Surprise | 0.1472 | 0.382 | 0.09 | 0.02 | 0.11 | 0.12 | 0.05 | 0.07 | 0.02 | 0.04 | -0.01 | 0.11 |
| Surprise Percentage | 22.8998% | 128.1879% | 27.2727% | 5.1282% | 32.3529% | 37.5% | 16.6667% | 26.9231% | 11.7647% | 14.8148% | -3.5714% | 26.1905% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CPRX
2026-06-05 20:40:15
Catalyst Pharmaceuticals' Chief Medical Officer, William T. Andrews, reported the exercise of 3,052 restricted stock units (RSUs) into common stock. Of these, 743 shares were withheld for tax obligations, leaving him with a direct holding of 2,309 shares. The RSUs vest in equal annual tranches from 2026 to 2030.
2026-06-05 12:11:18
This article provides an overview of Catalyst Pharmaceuticals' (CPRX) SEC filings, including its 10K forms, 8K current reports, and Form 4 insider ownership changes. It highlights the importance of these filings for investors to access verified financial data and track company events and insider trading activity. The most recent filing was a Form 4 submitted on June 5, 2026, detailing an ownership change.
2026-06-03 23:10:43
Quantitative Research Desk has published an analysis on Catalyst Pharmaceuticals Inc. (CPRX), identifying neutral near and mid-term readings but a potentially moderating long-term positive bias. The report offers three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—each with specific entry, target, and stop-loss levels, and emphasizes sophisticated risk management. No clear price positioning signal was identified, but the absence of resistance levels above the current price suggests compelling upside potential.
2026-06-03 11:18:00
This article provides a detailed AI-driven analysis of Catalyst Pharmaceuticals Inc. (CPRX) stock, outlining various trading strategies for different risk profiles. It highlights neutral near and mid-term readings but a positive long-term bias, and offers specific entry, target, and stop-loss zones for position, momentum breakout, and risk hedging strategies. The analysis emphasizes the utilization of predictive AI for optimizing trading decisions and managing risk.
2026-06-03 06:39:49
This article analyzes the valuation of Catalyst Pharmaceuticals Inc (CPRX), determining it to be undervalued. Based on its forward PE ratio of 12.87 compared to a five-year average of 14.23, and a current price of $31.27 versus a fair price range of $41.66 to $58.16, CPRX is considered undervalued by 24.94%. The analysis also details its Price-to-Book ratio, Free Cash Flow yield, and compares its Price-to-Sales ratio against competitors.
2026-05-29 20:39:33
H.C. Wainwright has reiterated its Hold rating for Catalyst Pharmaceuticals (CPRX.US) and maintained its target price at $31.5. This indicates a consistent outlook on the company's stock value from the analyst firm.
